Flubromazepam
Benzodiazepine designer drug
From Wikipedia, the free encyclopedia
Flubromazepam is a benzodiazepine derivative which was first synthesized in 1960,[1] but was never marketed and did not receive any further attention or study until late 2012 when it appeared on the grey market as a novel designer drug.[2][3][4][5][6][7][8]
- CA: Schedule IV
- DE: Anlage II (Authorized trade only, not prescriptible)
- UK: Class C
- US: Unscheduled (Virginia, Schedule I)
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 106 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.428.842 |
| Chemical and physical data | |
| Formula | C15H10BrFN2O |
| Molar mass | 333.160 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It is a structural analog of phenazepam in which the chlorine atom has been replaced by a fluorine atom.
An alternate isomer, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one or "iso-flubromazepam",[9] may have been sold under the same name.[2]

Legal status
United Kingdom
In the UK, flubromazepam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[10]
United States
Flubromazepam, clonazolam, and flubromazolam are Schedule I controlled substances under Virginia State Law.[11]